Impact of anticoagulation levels on outcomes in patients undergoing elective percutaneous coronary intervention: insights from the STEEPLE trial
1 Institut de Cardiologie (AP-HP) and INSERM Unit no. 856, Centre Hospitalier Universitaire Pitié-Salpêtrière, Paris, France
2 Division of Cardiology, Newark Beth Israel Medical Center, Newark, NJ, USA
3 sanofi-aventis, Paris, France
4 UZ Gasthuisberg, Leuven, Belgium
5 Servicio de Cardiología, Hospital Universitario, Madrid, Spain
6 Cardiology Department, Flinders Medical Centre, Adelaide, SA, Australia
7 Service de Cardiologie, Hôpital Bichat, Paris, France
8 Green Lane Cardiovascular Service, Auckland City Hospital, Auckland, New Zealand
9 Montreal Heart Institute, Université de Montréal, Montréal, Canada
10 Division of Cardiology, University of Kentucky, Lexington, KY, USA
Received 4 May 2007; revised 18 December 2007; accepted 8 January 2008.
* Corresponding author. Tel: +33 1 42 16 30 06, Fax: +33 1 42 16 29 31, Email: gilles.montalescot{at}psl.aphp.fr or gilles.montalescot{at}psl.ap-hop-paris.fr
Aims: To determine the relationship between anticoagulation levels during percutaneous coronary intervention, and ischaemic events and bleeding.
Methods and results: A sub-analysis from the STEEPLE trial was conducted. Pre-defined target anticoagulation levels were achieved in 86% of patients receiving enoxaparin, compared with 20% receiving unfractionated heparin (UFH) (P < 0.001). A significant relationship was observed between anti-Xa levels > 0.9 IU/mL and covariate-adjusted rate of non-coronary artery bypass graft-related major and minor bleeding [odds ratio (OR) 1.6, 95% CI 1.0–2.5 for each unit of anti-Xa; P = 0.03]; anti-Xa levels and covariate-adjusted incidence of death, myocardial infarction, or revascularization showed no significance (P = 0.47). Major bleeding increased significantly with an activated clotting time (ACT) > 325 s (OR 1.6, 95% CI 1.1–2.2 per 100 s; P = 0.04). A significant relationship with increasing ischaemic events was observed when ACT was < 325 s (OR 0.7, 95% CI 0.2–0.8 per 100 s; P = 0.006) indicating a narrow therapeutic window.
Conclusion: Target anticoagulation levels were achieved more readily in patients receiving enoxaparin. An anti-Xa level of up to 0.9 IU/mL has a good safety and efficacy profile; poor achievement of target ACT with UFH makes assessing the optimal range difficult.
Key Words: Anticoagulation • Enoxaparin • Percutaneous coronary intervention • Unfractionated heparin
This paper was guest edited by Freek W.A. Verheugt, Department of Cardiology, Heartcenter, University Medical Center Nijmegen, PO Box 9101, Nijmegen 6500 HB, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Silvain, F. Beygui, A. Ankri, A. Bellemain-Appaix, A. Pena, O. Barthelemy, G. Cayla, V. Gallois, S. Galier, D. Costagliola, et al. Enoxaparin Anticoagulation Monitoring in the Catheterization Laboratory Using a New Bedside Test J. Am. Coll. Cardiol., February 16, 2010; 55(7): 617 - 625. [Abstract] [Full Text] [PDF]
|
|